A New Development of Molecular Design Utilizing Novel Hydrophobic Structures

2017 Fiscal Year Final Research Report

• Project/Area Number: 26460151
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Drug development chemistry
• Research Institution: Tohoku Medical and Pharmaceutical University
• Principal Investigator: ENDO Yasuyuki 東北医科薬科大学, 薬学部, 教授 (80126002)
• Co-Investigator(Kenkyū-buntansha): 猪股 浩平 東北医科薬科大学, 薬学部, 准教授 (60221785) ; 太田 公規 東北医科薬科大学, 薬学部, 講師 (90347906)
• Co-Investigator(Renkei-kenkyūsha): TAN-NO Koichi 東北医科薬科大学, 薬学部, 教授 (20207260) ; NAKAGAWASAI Osamu 東北医科薬科大学, 薬学部, 准教授 (50296018)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 医薬分子設計 / 核内受容体 / エストロゲン受容体 / アンドロゲン受容体 / アゴニスト / アンタゴニスト

Outline of Final Research Achievements

In this project, we focused design and synthesis of new estrogen receptor ligands and androgen receptor ligands utilizing a new hydrophobic structure such as boron cluster, carboranes. We have developed lead compounds for anti-osteoporosis drugs and anti-prostate cancer drugs which are effective for resistant cancer cells against conventional anticancer drugs. On the other hand, he present study has demonstrated that a new carborane compound BE360 has antidepressant and antidementia effects related by hippocampal cell proliferation. These results indicate that BE360 may have a valuable therapeutic potential against depression and neurodegenerative diseases such as AD.

Free Research Field

創薬化学